Drug Trial Radar · NCT05445843
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
95
Actual
Start
Dec 6, 2022
Primary completion
Nov 4, 2024
Study completion Oct 28, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C mutation and have a PD-L1 expression \< 1% (cohort A) or a PD-L1 expression ≥ 1% and an STK11 co-mutation (cohort B).
Conditions
- Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Interventions
JDQ443Drug
JDQ443 per os (PO) 200 mg twice a day continuously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) as Determined by the Investigator in Cohort ATime frame: Up to approximately 22 months
Locations
45 sites in 19 countries. Site status is shown where the registry gives one.
The Brown University Oncology Group
Providence, Rhode Island
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Pilar, Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Novartis Investigative Site
Feldkirch, Austria
Novartis Investigative Site
Wels, Austria
Novartis Investigative Site
Sint-Niklaas, Oost Vlaanderen, Belgium
Novartis Investigative Site
Roeselare, West-Vlaanderen, Belgium
Novartis Investigative Site
Belo Horizonte, Brazil
Novartis Investigative Site
Rio de Janeiro, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Bron, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Saint-Herblain, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Marseille, Bouches Du Rhone, France
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Oldenburg, Germany
Novartis Investigative Site
Tübingen, Germany
Novartis Investigative Site
Kempten (Allgäu), Bavaria, Germany
Novartis Investigative Site
Halle, Saxony-Anhalt, Germany
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Mátraháza, Hungary
Novartis Investigative Site
Thellakom Kottayam, Kerala, India
Novartis Investigative Site
Varanasi, Uttar Pradesh, India
Novartis Investigative Site
Bari, BA, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Orbassano, TO, Italy
Novartis Investigative Site
George Town, Pulau Pinang, Malaysia
Novartis Investigative Site
Kuching, Sarawak, Malaysia
Novartis Investigative Site
Breda, North Brabant, Netherlands
Novartis Investigative Site
Leeuwarden, Provincie Friesland, Netherlands
Novartis Investigative Site
Porto, Portugal
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.